Current
15.8×
5-Year Average
11.8×
All-Time High
308.7×
All-Time Low
5.8×
P/FCF Ratio daily chart for Gilead Sciences (GILD)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
Historical P/FCF Ratio for Gilead Sciences (GILD) from 2001 to 2025
| 2025 | $152.44B | $9.46B | 16.1× | +4.9× | |
| 2024 | $115.28B | $10.30B | 11.2× | -2.4× | |
| 2023 | $101.10B | $7.42B | 13.6× | +0.7× | |
| 2022 | $107.48B | $8.34B | 12.9× | +4.4× | |
| 2021 | $91.20B | $10.80B | 8.4× | -1.3× | |
| 2020 | $73.12B | $7.52B | 9.7× | -0.2× | |
| 2019 | $82.26B | $8.32B | 9.9× | -0.9× | |
| 2018 | $80.69B | $7.48B | 10.8× | +2.5× | |
| 2017 | $93.63B | $11.31B | 8.3× | +2.5× | |
| 2016 | $94.24B | $16.25B | 5.8× | -1.6× | |
| 2015 | $145.31B | $19.58B | 7.4× | -4.2× | |
| 2014 | $141.96B | $12.26B | 11.6× | -28.0× | |
| 2013 | $115.19B | $2.91B | 39.5× | +19.6× | |
| 2012 | $55.73B | $2.80B | 19.9× | +11.3× | |
| 2011 | $30.19B | $3.51B | 8.6× | -2.0× | |
| 2010 | $29.30B | $2.77B | 10.6× | -3.1× | |
| 2009 | $38.94B | $2.85B | 13.7× | -8.6× | |
| 2008 | $46.59B | $2.09B | 22.3× | -3.0× | |
| 2007 | $42.64B | $1.69B | 25.3× | -1.4× | |
| 2006 | $29.70B | $1.11B | 26.7× | -9.2× | |
| 2005 | $23.97B | $667.13M | 35.9× | +3.1× | |
| 2004 | $15.09B | $460.01M | 32.8× | -27.2× | |
| 2003 | $11.76B | $196.00M | 60.0× | -57.4× | |
| 2002 | $6.67B | $56.81M | 117.4× | — | |
| 2001 | $6.27B | −$114.46M | — | — |
- 202516.1×
- 202411.2×
- 202313.6×
- 202212.9×
- 20218.4×
- 20209.7×
- 20199.9×
- 201810.8×
- 20178.3×
- 20165.8×
- 20157.4×
- 201411.6×
- 201339.5×
- 201219.9×
- 20118.6×
- 201010.6×
- 200913.7×
- 200822.3×
- 200725.3×
- 200626.7×
- 200535.9×
- 200432.8×
- 200360.0×
- 2002117.4×
- 2001—
About P/FCF Ratio at Gilead Sciences (GILD)
Gilead Sciences (GILD) P/FCF ratio is 15.8× as of June 5, 2026. The 5-year average is 11.8×. The sector median currently stands at 19.8×. The current ratio is at the 86th percentile of its own 10-year history.
Gilead Sciences (GILD) historical P/FCF ratio has ranged from a low of 5.8× (2016) to a high of 308.7× (2002) in the available daily series.
The price-to-free-cash-flow (P/FCF) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) free cash flow. It is calculated as market cap ÷ TTM free cash flow, where free cash flow = operating cash flow − capital expenditures. Because FCF cannot be inflated by non-cash accounting items, P/FCF is often considered a cleaner measure of "earnings-power valuation" than P/E — especially for capital-intensive businesses where depreciation diverges from real cash outflows.
Gilead Sciences P/FCF Ratio by Year
Gilead Sciences P/FCF Ratio 2025: 16.1×
Gilead Sciences (GILD) P/FCF ratio in 2025 was 16.1×, expanded from 11.2× the prior year.
Gilead Sciences P/FCF Ratio 2024: 11.2×
Gilead Sciences (GILD) P/FCF ratio in 2024 was 11.2×, contracted from 13.6× the prior year.
Gilead Sciences P/FCF Ratio 2023: 13.6×
Gilead Sciences (GILD) P/FCF ratio in 2023 was 13.6×, expanded from 12.9× the prior year.
Gilead Sciences P/FCF Ratio 2022: 12.9×
Gilead Sciences (GILD) P/FCF ratio in 2022 was 12.9×, expanded from 8.4× the prior year.
Gilead Sciences P/FCF Ratio 2021: 8.4×
Gilead Sciences (GILD) P/FCF ratio in 2021 was 8.4×.
Sector peers by P/FCF Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/FCF Ratio — table
Healthcare peers of Gilead Sciences (GILD), ranked by P/FCF ratio.
| 18.5× | |
| 17.8× | |
| 17.8× | |
| 16.9× | |
| 16.7× | |
| 16.4× | |
| 16.3× | |
| 15.9× | |
| 14.0× | |
| 13.5× | |
| 12.9× | |
| 12.5× | |
| 12.4× | |
| 12.2× | |
| 12.1× | |
| 11.3× | |
| 10.7× | |
| 10.4× | |
| 10.3× | |
| 10.0× | |
| 9.6× | |
| 9.1× | |
| 9.1× | |
| 6.9× | |
| 2.5× |
- 18.5×
- 17.8×
- 16.9×
- 16.7×
- 16.4×
- 13.5×
- 12.9×
- 12.4×
- 10.7×
- 10.3×
- 9.1×
- 9.1×
- 6.9×
- 2.5×
Frequently asked questions
Gilead Sciences (GILD) Key Financials
Charts, filings, and peer comparison for every metric